Dr Nilsson talks to ecancertv at AACR 2015 about the development of a blood test which regularly monitors for the presence of the rearrangement of the EML4-ALK gene fusion in patients with non-small cell lung cancer (NSCLC), helping clinicians predict the outcome of treatment with crizotinib.
Read the news story for more.